Αποτελέσματα Αναζήτησης
11 Οκτ 2021 · In 40-year-olds, the effectiveness for preventing SARS-CoV-2 infection was 11% (-30 to 39) for the Oxford-AstraZeneca vaccine and 38% (95% CI, 9 to 59) for the Pfizer-BioNTech vaccine. The effectiveness increased to 94% (81 to 98) and 82% (52 to 94), respectively, in those aged 90 years.
13 Μαΐ 2021 · In this analysis we estimated the effect of vaccination with the BNT162b2 and ChAdOx1-S vaccines on confirmed symptomatic covid-19 in adults aged 70 years and older with one and two doses; estimated vaccine effectiveness against the B.1.1.7 variant; and estimated covid-19 hospital admissions and case fatality rates among vaccinated and ...
2 Μαρ 2021 · “Combined with the effect against symptomatic disease, this indicates that a single dose of either vaccine is around 80% effective at preventing hospital admissions and a single dose of the Pfizer vaccine is 85% effective at preventing death with covid-19,” the paper said.
3 Μαρ 2022 · Two doses of Pfizer-BioNTech vaccine provided protection against COVID-19 in persons aged 12–17 years during Delta predominance, but data during Omicron predominance and among children aged 5–11 years are lacking. What is added by this report?
The first dose of the Oxford–AstraZeneca vaccine was associated with a vaccine effect of 94% for COVID-19-related hospitalisation at 28–34 days post-vaccination. Combined results (all vaccinated participants, whether Pfizer–BioNTech or Oxford–AstraZeneca) showed a significant vaccine effect for prevention of COVID-19-related ...
You have permission to use, distribute, and reproduce these in any medium, provided the source and authors are credited. All the software and code that we write is open source and made available via GitHub under the permissive MIT license. All other material, including data produced by third parties and made available by Our World in Data, is ...
3 Ιαν 2022 · The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) gave emergency use authorisation to three vaccines against COVID-19 between December 2020 and January 2021, namely the Pfizer/BioNTech BNT162b2 mRNA, Oxford/AstraZeneca ChAdOx1 nCoV-19 adenoviral AZD1222; and Moderna mRNA-1273 vaccines.
